secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-003811
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie terminates TREM2 program and collaboration with Alector after Phase 2 miss
--------------------------------------------------------------------------------

- INVOKE-2 Phase 2 trial of AL002 in early Alzheimer's disease did not meet primary endpoint (announced Nov 25, 2024).
- AbbVie provided written termination notice on Jan 9, 2025 for TREM2 program and the overall collaboration agreement.
- Termination effective 30 days from receipt of Jan 9 termination letter; no other programs remain in the partnership.
- The TREM2 program was the only remaining program under the AbbVie Agreement, so termination ends the entire collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025003811/0000950170-25-003811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025003811/alec-20250109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer